Supply Chain

Pharmaceutical Research and Manufacturers of America — the drug industry's largest lobbying group — broke its silence on the controversy surrounding the high price of Marathon Pharmaceutical's newly approved muscular dystrophy drug, reports Endpoints News.

Here are seven articles published by Becker's Hospital Review this past week highlighting new survey findings on the hospital supply chain, a safety warning from the Food and Drug Administration and more scrutiny of high drug prices, among other topics.

The American Red Cross is encouraging eligible donors in the Northeast region to give blood or platelets after recent winter stores magnified an already severe blood shortage, reports NH1.

Marathon Pharmaceuticals' $89,000 price tag for its newly approved Duchenne muscular dystrophy drug has drawn criticism from many lawmakers, including Sen. Bernie Sanders, I-Vt., reports CBS New York.

Arlington-based Texas Health Resources recently expanded its partnership with Inventory Optimization Solutions.

Integra LifeSciences Holdings Corp. will purchase Johnson & Johnson's Codman neurosurgery business for $1.05 billion, reports Reuters.

Merck on Tuesday halted a late-stage clinical trial of its Alzheimer's drug verubecestat after an independent study discovered the treatment had "virtually no chance" of proving effective, reports CNN.

Many health systems struggle to standardize products and contract prices across their facilities.

"Reciprocal approval" would allow the Food and Drug Administration to automatically sign off on new drugs already approved in other countries. While some healthcare players believe this strategy could help lower drug prices and give patients access to treatments sooner,…

Some pharmaceutical executives fear President Donald Trump's call for a deregulated Food and Drug Administration would make it harder for drugmakers to gain insurance coverage for new treatments, reports Reuters.